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OBJECTIVES: Describe venous thromboembolism (VTE) treatment patterns and clini-
cal outcomes among cancer patients. METHODS: Adult patients (age > 18 years) 
with ≥ 2 VTE diagnosis claims (ICD-9-CM codes) in an outpatient setting or one 
VTE diagnosis in an inpatient setting were selected from the Humedica database 
(01JAN2008-31MAR2014). Continuous health plan enrollment 6 months pre-index 
date (VTE diagnosis) was required. Cancer patients (ICD-9 codes for cancer diagno-
sis, medication use, radiation therapy, or surgery) were differentiated from active 
cancer patients (ICD-9 codes for cancer diagnosis and treatment) based on diagnosis 
codes during baseline period. VTE treatment patterns with low molecular weight 
heparin (LMWH), unfractionated heparin (UFH), fondaparinux and oral anticoagu-
lants (OACs) were evaluated. Incidence rate (in person-years) was calculated for 
clinical outcomes: VTE recurrence, bleeding, major bleeding and clinically relevant 
non-major bleeding. RESULTS: Patients with active cancer were on average sicker 
(Charlson Comorbidity Index score: 6.7 vs. 2.9) and had higher proportions of numer-
ous comorbid conditions, including respiratory disease (52.7% vs. 40.4%), hepatic 
disease (14.9% vs. 6.1%) and baseline bleeding (30.4% vs. 17.8%) compared to all 
cancer patients. More than 70% of cancer patients were prescribed anticoagulants, 
and the majority received a combination of parenteral andoral anticoagulant treat-
ment. A higher proportion of active cancer patients received only parenteral anti-
coagulant compared to all cancer patients (26.1% vs. 16.2%), and LMWH was the 
most commonly prescribed parenteral anticoagulant. The incidence rate of VTE 
recurrence (24.7 vs. 14.3 per 100 person-years) and major bleeding events (31.2 vs. 
15.9 per 100 person-years) was higher among active cancer patients than all VTE 
cancer patients. CONCLUSIONS: Approximately 30% of VTE cancer patients did 
not receive any anticoagulation, with difference in treatment patterns between 
VTE cancer and active cancer patients. Active cancer patients had higher incidence 
rates of VTE recurrence and bleeding events compared to all VTE cancer patients.
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OBJECTIVES: Sleep disorder (SD) is a common problem for patients with psoriasis 
and both psoriasis and SD are each strongly associated with cardiovascular disease 
and metabolic syndrome. The aim of this study was to evaluate the impact of SD 
on psoriatics in terms of cardiovascular disease development. METHODS: We con-
ducted a cohort study investigating 99,628 adults with psoriasis from 2004 to 2010 
by using the Taiwan National Health Insurance Research Database. Concomitant 
SD with psoriasis was defined as the development of SD within 6 months after the 
diagnosis of psoriasis. The risk of ischemic heart disease (IHD) in patients with SD 
compared with patients without SD was analyzed using Cox proportional hazards 
regression models including sex, age, medications and comorbidities. RESULTS: 
After adjustment for covariates, psoriasis patients with concomitant SD had sig-
nificantly higher risks for IHD (adjusted Hazard ratio (aHR), 1.25; 95% confidence 
interval (CI), 1.22–1.29) than patients without SD. Moreover, the increased risk of 
IHD conferred by SD paralleled the dose of hypnotics used. The SD effect on the risk 
of IHD was higher in young patients aged 18 to 34 than in middle-aged and older 
adults. Further stratified analysis showed that SD, including apnea and non-apnea 
SD, remained significantly associated with elevated risk of IHD in all subgroups 
of psoriasis: mild, severe psoriasis and patients with/without psoriatic arthri-
tis. CONCLUSIONS: Psoriasis patients with SD were at increased risk for develop-
ing IHD compared to patients without SD, with higher attributable risk in younger 
patients. Moreover, the risks of IHD increased in parallel with the severity of SD.
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OBJECTIVES: To examine the performance of various administrative claims-based 
algorithms with varying observation times for identifying patients with hyperten-
sion. METHODS: This retrospective analysis utilized administrative claims data 
linked with electronic medical records (EMR). Patients were identified in claims 
data using two observation time periods, 11/2010 to 12/2013 (EMR data availabil-
ity) and 01/2006 to 12/2013 (entire claims data availability). Various claims-based 
hypertension algorithms were defined using ICD-9 diagnosis codes from medical 
claims and antihypertensive medications from pharmacy claims. Sensitivity and 
specificity were computed for each of claims-based algorithm and the two obser-
vation time periods using hypertension diagnoses from the EMR patient problem 
list as the gold standard. RESULTS: From a total of 10,864 patients with integrated 
data, 3,272 were identified with hypertension in EMR. When using claims in the 
same period as EMR availability, medical claims only based algorithms requiring 
one, two, or three diagnoses resulted in sensitivities of 83.3%, 75.0%, and 67.8% 
and specificities of 89.4%, 93.0%, and 94.6%, respectively, while the medical plus 
pharmacy claims based algorithms requiring pharmacy claim for an antihyperten-
sive plus one, two, or three diagnoses resulted in sensitivities of 74.3%, 69.6%, and 
64.0% and specificities of 92.7%, 94.2%, and 95.2%, respectively. By contrast, when 
using the entire claims data availability, the same medical claims only based algo-
rithms resulted in sensitivities of 91.9%, 89.4%, and 86.2% and specificities of 77.3%, 
81.8%, and 84.1%, respectively, while the same medical plus pharmacy claims based 
algorithms resulted in sensitivities of 85.6%, 84.3%, and 82.1% and specificities of 
85.3%, 86.4%, and 87.2%, respectively. CONCLUSIONS: Claims-based algorithms for 
identifying hypertensive patients vary on criteria and observation time of the data. 
Sensitivities are higher with medical claims only algorithms while specificities are 
higher when pharmacy claims are combined with medical claims. Longer observa-
tion time results in increased sensitivities and decreased specificities.
cases. Mean BMI was 24.54 ± 5.73 Kg/m2. Forty eight patients were given combina-
tion therapy and 52 patients were treated with a single drug. A total of 61 (61%) cases 
presented with some forms of ADR whereas 39 responded with no any ADRs. But 
from Naranjo’s Algorithm, only one case had definite ADR, 23 probable, 34 possible 
and four doubtful ADR. Presence of ADR was not associated with sex (p value 0.997, 
OR 1.002) ADR was also not significantly associated with the type of therapy; mono 
or combination therapy (p value 0.140) though combination therapy was associ-
ated with higher risk (OR= 1.916) Thirty three cases presented with cardiovascular 
complaints (21 cases of postural hypotension, three pedal edema and others), 18 
with CNS complaints, six with respiratory complaints (dry cough), five with der-
matological complaints like dermatitis and rashes, 11 with fatigue and four with 
gynaecomastia. Amlodipine, furosemide, spironolactone, enalapril, losartan were 
the common drugs causing ADRs. CONCLUSIONS: The above findings would be 
useful for physicians in rational prescribing of the antihypertensive medicines. 
Cardiovascular complaints were the most common presented ADRs and amlodipine 
the most common drug.
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OBJECTIVES: Patient characteristics and bleeding and recurrence risk of venous 
thromboembolism (VTE) were assessed among patients in the Veterans Health 
Administration (VHA) population. METHODS: Adult patients (≥ 18 years) with VTE 
(International Classification of Diseases, 9th Revision, Clinical Modification codes: 
451-453, 671.3, 671.4 and 671.9 deep vein thrombosis [DVT]; 415.1, 673.2, 673.8 pul-
monary embolism [PE]) were identified from the VHA Medical SAS datasets. The 
index date was defined as the first VTE diagnosis date between 01APR2006 and 
30SEP2012. Patients were required to have ≥ 2 outpatient VTE diagnosis claims 
within 3 weeks and one inpatient stay with a VTE diagnosis, continuous health 
plan enrollment for 6 months pre-index date and no VTE diagnosis (V12.51, V12.52) 
in the baseline period. Patient data were assessed until the earlier of death or end 
of the study period. Outcomes of interest included VTE recurrence, major bleeding 
and clinically-relevant non-major bleeding (CRNM). The incidence rate (per 100 
person-year) was calculated for VTE recurrence and bleeding outcomes. RESULTS: 
Total 88,280 VTE patients were identified, of which 67.6% had DVT and 24.9% had PE. 
VTE patients were mean age 66 years, 95.9% were male and more often resided in 
the Southern U.S. region (37%). The baseline Charlson comorbidity index score was 
3.3 and common comorbid conditions included hypertension (56.00%), respiratory 
disease (34.3%) and heart disease (34.3%). Non-steroidal anti-inflammatory drugs 
(60.10%), antidepressants (33.00%) and anticoagulants (36.8%) were also frequently 
prescribed in the baseline period. During the follow-up period, 37.5% of VTE cases 
occurred in outpatient settings and 62.50% occurred in inpatient settings. The inci-
dence rate for VTE recurrence (20.7%) was 10.5 per 100 person-years, major bleed-
ing (21.9%) was 10.9 per 100 person-years and CRNM (23.00%) was 12.1 per 100 
person-years. CONCLUSIONS: U.S. veteran patients diagnosed with VTE had fre-
quent comorbid conditions and were at high-risk for bleeding and VTE recurrence.
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OBJECTIVES: Recent studies produced variable results regarding the impact of person-
alized warfarin dosing on clinical outcomes. Personalized warfarin dosing was imple-
mented at the University of Illinois Hospital & Health Science System (UI-Health) 
with daily dose recommendations provided by a pharmacist-guided pharmacoge-
netic (PGx) consult service. Our aim was to compare warfarin-related hospitaliza-
tions post therapy initiation between inpatients managed by the PGx service and 
historical controls. METHODS: This was a prospective cohort study that compared 
warfarin-related hospitalizations, due to bleeding or thromboembolism over 30 and 
90 days, in patients managed by the PGx service and historical controls. In general-
ized regression models with a Poisson error distribution assumption, we compared 
the incidence rates for the composite endpoint of bleeding or thrombosis related 
hospitalizations. Time to first re-admission due to warfarin-related complications 
was analyzed using log-rank tests and Cox-proportional hazard regression models. 
Analyses were adjusted for warfarin indication. RESULTS: There were totals of 6 and 
15 warfarin-related hospitalizations in the PGx (n= 389) and control (n= 308) groups 
respectively 90 days post index hospitalization, with an estimated incidence rate 
ratio (IRR) of 0.45 (95% Confidence Interval [CI] 0.12 – 0.81). This benefit was still seen 
after risk adjustment (IRR 0.35, 95% CI 0.13 – 0.97). In time to event analyses, Kaplan-
Meier estimators for the composite endpoint also showed lower events in the PGx 
group (p= 0.04 at day 30 and 0.08 at day 90). In addition, the hazard ratio (HR) from a 
Cox-proportional model adjusted for the intervention also favored the Pgx group at 
30 days (HR 0.189 [p= 0.05]). CONCLUSIONS: A pharmacist-guided pharmacogenetic 
service lowers warfarin related hospitalizations a 3 months post therapy initiation.
PCV5
CliniCal outComeS anD treatment PatternS of VenouS 
thromboemboliSm among CanCer PatientS in a large CommerCial 
DatabaSe
Masseria C.1, Kariburyo M.F.2, Mardekian J.1, Lee T.1, Phatak H.3, Baser O.4, Xie L.2
1Pfizer Inc., New York, NY, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3Bristol-Myers 
Squibb Company, Princeton, NJ, USA, 4STATinMED Research, The University of Michigan, MEF 
University, Ann Arbor, MI, USA
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A131
antipsychotic-stimulant group. No statistically significant difference was found in 
the risk of cardiovascular events among patients with mood stabilizer-stimulant 
combination (HR= 0.98, 95% Confidence Interval, 95% CI: 0.49-1.99) or antipsy-
chotic-stimulant combination (HR= 0.57, 95% CI: 0.31-1.05) compared to stimulant 
monotherapy. CONCLUSIONS: The current study did not find any difference in the 
cardiovascular risk after addition of mood stabilizer or atypical antipsychotic to 
stimulant monotherapy in patients with ADHD and bipolar disorder. More studies 
are needed to evaluate overall safety profiles of these therapeutic combinations in 
patients with comorbid ADHD and bipolar disorder.
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OBJECTIVES: Clinical trials showed insignificant effects of statins on preventing car-
diovascular diseases(CVD) among hemodialysis patients. This study is to examine the 
association between discontinuation of statin use after hemodialysis and the risk of 
CVD. METHODS: We conducted a population-based retrospective cohort study using 
year 1997-2008 National Health Insurance Research Database. We selected patients 
who are 20 years old or above and first time receiving maintenance hemodialysis. 
The selected patients were also those prescribed statins at least once in the 180 
days before the first hemodialysis. We excluded the patients who had medical his-
tory of kidney transplantation or maintenance peritoneal dialysis. Continuous use 
of statins was defined as receiving prescriptions of statins in the first 90 days after 
hemodialysis. We used the Cox proportional hazards model to analyze the associa-
tion between the discontinuation status and the risk of hospitalization or surgeries 
for coronary heart diseases (CHD) and non-hemorrhagic stroke. The propensity score 
method was used to adjust the self-selection bias in the statin user and non-user 
groups. RESULTS: Among 8,949 patients examined, 2,079 (23.2%) patients used statins 
in the first 90 days after hemodialysis. After adjusted by the propensity score, the Cox 
model showed discontinuation of statin use in the first 90 days after dialysis was not 
associated with higher risk of hospitalization or surgeries for CHD and non-hem-
orrhagic stroke (HR 0.55ï¿½, 95% CI 0.50, 0.61) compared to statin users. The results 
were consistent when stratifying the patients into those with medical history of CVD 
(n= 5288, HR 0.53ï¿½, 95% CI 0.47, 0.60) and those without (n= 3661, HR 0.61, 95% CI 
0.50, 0.74). CONCLUSIONS: Discontinuation of statin use after hemodialysis does not 
increase the risk of hospitalization or surgeries for CHD and non-hemorrhagic stroke. 
However, this result cannot rule out the possible association between the severity of 
hypercholesterolemia or predicted risk of CVD and statin use.
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OBJECTIVES: A novel genotype-guided personalized warfarin dosing (PGx) service 
was implemented at the University of Illinois Hospital & Health Sciences System. 
The aim of this study was to examine the impact of race on the association between 
the (PGx) service and anticoagulation related clinical outcomes. METHODS: 
Multivariate linear, logistic, and survival models were used to examine differences 
across race in the association between the PGx service and several clinical outcomes. 
These models were adjusted for confounders, and inverse probability treatment 
weight propensity scoring was used. Our primary outcome of interest was time to 
first therapeutic INR. RESULTS: A total of 339 patients managed by the PGx service 
(mean age 56±16 years; 61% African-American; 55% female) and 299 historical con-
trols (mean age 54±16 years; 74% African-American, 64% female) were included. 
In our primary outcome, the treatment effect in time to first therapeutic INR was 
significantly higher in African-Americans compared to Caucasians (HR: 1.86, 95%CI: 
1.3, 2.8 vs. HR: 1.24, 95%CI: 0.4, 3.8, respectively). The treatment effect in time in 
therapeutic international normalized ratio (INR) range was significantly higher in 
African-Americans than in Caucasians over the initial 7 days of therapy (β : 5.52 
days, 95% CI: 1.4, 9.6 vs. β : 0.78, 95%CI: -9.3, 10.8, respectively). The treatment effect 
in proportion of INRs at extremes (< 1.5 and > 4) was lower in African-Americans 
compared to Caucasians (β : -25.56, 95% CI: -31.6, -19.6 vs. β : -22.46, 95% CI: -36.8, 
-8.2, respectively). Additionally, relative to Caucasians, African-Americans in the PGx 
group were 2.17 times more likely to have an INR in therapeutic range at discharge 
(OR: 2.17, 95% CI: 1.0, 4.7). CONCLUSIONS: A novel genotype-guided personalized 
warfarin service was positively associated with anticoagulation related clinical out-
comes, and this association was stronger in African-American patients.
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OBJECTIVES: eHealth is the transfer of health resources, care, and data by electronic 
means and has the potential to promote reductions in the cost of care. It has been 
employed by medical professionals to manage chronic diseases outside of a clinical 
setting, provide useful data for decision making, and deliver timely information and 
care to the patient. This review assesses the use of eHealth programs in chronic 
disease management and identifies the settings and patient populations that have 
resulted in successful outcomes. METHODS: A systematic literature review was 
conducted in Embase, Medline, CINAHL, and PsycINFO. Inclusion criteria were 
English language studies since 2005 evaluating the efficacy of an eHealth program 
on patients with chronic disease(s). Studies in which e-mail communication was 
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OBJECTIVES: Venous thromboembolism (VTE) is one of the major complications 
after major orthopedic surgeries (MOS). In 2011, FDA approved rivaroxaban for VTE 
prevention among patients undergoing MOS. The aim of our study is to empirically 
evaluate the comparative effectiveness of rivaroxaban, warfarin, and low molecu-
lar weight heparins (LMWHs) for VTE prevention among MOS patients using “real 
world” data. METHODS: A cohort study using IMS Lifelink Plus (2006-2013) data 
compared the risk of VTE and major bleed events among MOS patients exposed 
to rivaroxaban, warfarin, LMWHs, or fondaparinux with those who are not anti-
coagulated within 7 days after their MOS-hospital discharge. Kaplan Meier curves 
and Cox proportional hazard models were used to assess the risk of VTE and major 
bleed events and to adjust for potential confounders. RESULTS: A cohort of 35,279 
MOS were included which provided 68,340 person years of follow up including 1,004 
rivaroxaban, 7,339 warfarin, 5,692 LMWH, 841 fondaparinux exposed patients and 
20,403 patients who did not receive an initial anticoagulant. Risk of VTE was low-
est for rivaroxaban (H.R.= 0.282; 95%CI:0.156-0.510) followed LMWHs (H.R.= 0.671 
[95%CI= 0.582-0.773]), fondaparinux (H.R.= 0.680 [95%CI = 0.485-0.951]) and warfa-
rin (H.R.= 0.872 [95%CI= 0.778-0.978]) when compared to no anticoagulant use in 
unadjusted cox models. After adjusting for potential confounders, only rivaroxaban 
(H.R.= 0.395 [95%CI= 0.215-0.742]) and LMWHs (H.R.= 0.755[95%CI= 0.643-0.873]) sig-
nificantly reduced the risk of VTE. However, these results were not significant in 
a sensitivity analysis using a more strict definition to detect VTEs in claims data. 
There were no bleed events for rivaroxaban users and the risk of bleed events were 
not significantly different among anticoagulants and non-anticoagulant exposure 
in both the adjusted and the unadjusted models. CONCLUSIONS: LMWHs and 
Rivaroxaban were associated with reduced VTE events and no detectable increase 
in major bleeds among MOS patients. These findings, particularly those on major 
bleed events, should be confirmed in larger study populations.
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OBJECTIVES: This analysis aimed to assess the potential clinical risk/benefits associ-
ated with the lifetime use of apixaban versus edoxaban in patients with non-valvular 
atrial fibrillation (NVAF) in the United States (US). METHODS: A Markov model was 
developed to extrapolate the observed clinical impact of apixaban versus a regimen 
of edoxaban starting at 60 mg at the lifetime horizon. Outcomes assessed included 
the number of clinical events avoided for every 1000 patients treated, number of 
patients needed to treat to prevent one stroke, and number of patients needed to 
harm with an additional major bleed. Key sources of inputs used to populate the 
model included: indirect comparison data versus edoxaban from published blinded 
randomized trials vs warfarin; US life tables for life expectancy; published literature 
for increased mortality related to outcome events modeled. RESULTS: In a cohort of 
1,000 patients, treatment with apixaban (at doses used in clinical trials) in comparison 
with edoxaban 60 mg resulted in 6 fewer strokes and caused 10 fewer major bleeds 
over the average projected lifetime. This translated in 172 patients needed to treat 
with apixaban versus edoxaban 60 mg to prevent one stroke with no additional major 
bleeding. The reduction in clinical events resulted in 29 additional discounted life-
years for the cohort of 1,000 patients treated with apixaban. CONCLUSIONS: Using an 
indirect comparison, lifetime use of apixaban is projected to increase life-expectancy 
versus edoxaban 60 mg QD in the US. It also appears to provide dual risk reduction 
based on efficacy and safety benefits versus edoxaban 60 mg starting regimen.
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OBJECTIVES: This study compared the cardiovascular safety of the addition of mood 
stabilizers or atypical antipsychotics to stimulant monotherapy in children and ado-
lescents diagnosed with ADHD and bipolar disorder. METHODS: This retrospective 
cohort study used 2004-2007 IMS LifeLink™ Health Plan Claims Database. Children 
and adolescents aged 6 to 17 years diagnosed with ADHD and bipolar disorder who 
initiated a new treatment with stimulants were followed for 12 months to compare 
the safety of addition of mood stabilizers or atypical antipsychotics to stimulant 
monotherapy. Only patients who had continuous eligibility 6 months before and 12 
months after the index stimulant date were selected. Exposure to a mood stabilizer 
or atypical antipsychotic agent after the initiation of the index stimulant treatment 
formed the primary exposure. The primary outcome was defined as the first hospi-
talization or emergency room (ER) visit for cardiovascular disorder identified using 
International Classification of Diseases- 9th Revision, Clinical Modification (ICD-9 
CM) codes. Cardiovascular risk was compared using time-varying Cox regression 
analysis adjusting for other cardiac risk factors. RESULTS: Of the 1,769 ADHD and 
bipolar patients, 48.28% were prescribed stimulants only, 16.68% were on mood 
stabilizer-stimulant combination and 35.05% were on antipsychotic-stimulant 
combination therapy. The incidence of cardiovascular events were 5.15% in the 
stimulants-only group, 4.75% in the mood stabilizer-stimulant group and 8.87% in 
